NeoGenomics, Inc. (NEO) experienced a pre-market plunge of 7.7% on Tuesday, February 18, as the company's fourth-quarter results fell short of analysts' expectations.
In its latest earnings report, NeoGenomics posted a quarterly loss per share of $0.12, missing the consensus estimate of $0.03 earnings per share. The company's revenue for the quarter came in at $172 million, slightly below the FactSet projection of $173.2 million.
Despite the disappointing quarterly performance, NeoGenomics reaffirmed its full-year 2025 guidance, which projects earnings per share of $0.20 and revenue of $733 million. However, investors seemed to focus more on the near-term disappointment, sending the stock tumbling in pre-market trading.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。